Payment overview · 2025
General Payments
$442.70
26 reported records · 7 companies
Healthcare provider profile · identity verified
Jeffrey A Prichard, PAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · PINEVILLE, WV · NPI 1508949595
Verified facts
What the public records show
CMS Open Payments records show Jeffrey A Prichard, PAC received $442.70 in general payments during 2025 across 26 reported records.
Novo Nordisk Inc accounted for 55.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $244.52 | 55.2% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $94.44 | 21.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.67 | 7.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.70 | 4.5% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.93 | 4.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.59 | 3.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.85 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $442.70 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $232.32 | 14 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $201.46 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $57.09 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $37.35 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.67 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.67 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 339 | 88 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 302 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 285 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 80 |
| Lisinopril | Lisinopril | 258 | 80 |
| Potassium Chloride | Potassium Chloride | 235 | 83 |
| Omeprazole | Omeprazole | 232 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 230 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 223 | 82 |
| Lorazepam | Lorazepam | 189 | 50 |
| Furosemide | Furosemide | 188 | 69 |
| Tramadol Hcl | Tramadol Hcl | 177 | 47 |
| Montelukast Sodium | Montelukast Sodium | 169 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 161 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 65 |
| Prednisone | Prednisone | 124 | 99 |
| Famotidine | Famotidine | 120 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 19 |
| Cefdinir | Cefdinir | 105 | 89 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 41 |
| Diazepam | Diazepam | 104 | 21 |
| Simvastatin | Simvastatin | 101 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 38 |
| Alprazolam | Alprazolam | 95 | 20 |
| Meloxicam | Meloxicam | 85 | 27 |
| Losartan Potassium | Losartan Potassium | 83 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 27 |
| Fluconazole | Fluconazole | 82 | 55 |
| Metformin Hcl | Metformin Hcl | 81 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 20 |
| Valsartan | Valsartan | 80 | 27 |
| Azithromycin | Azithromycin | 79 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 22 |
| Ozempic | Semaglutide | 72 | 15 |
| Synthroid | Levothyroxine Sodium | 68 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 24 |
| Cephalexin | Cephalexin | 65 | 59 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 24 |
| Repatha Sureclick | Evolocumab | 64 | 11 |
| Ezetimibe | Ezetimibe | 61 | 22 |
| Ibuprofen | Ibuprofen | 60 | 41 |
| Pregabalin | Pregabalin | 59 | 15 |
| Trulicity | Dulaglutide | 59 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 58 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 20 |
| Metformin Hcl Er | Metformin Hcl | 57 | 22 |
| Ondansetron Odt | Ondansetron | 57 | 39 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 34 |
| Eliquis | Apixaban | 56 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 48 |
| Clonazepam | Clonazepam | 54 | 11 |
| Trazodone Hcl | Trazodone Hcl | 54 | 18 |
| Amoxicillin | Amoxicillin | 49 | 38 |
| Januvia | Sitagliptin Phosphate | 48 | 16 |
| Meclizine Hcl | Meclizine Hcl | 48 | 27 |
| Nystatin | Nystatin | 48 | 27 |
| Baclofen | Baclofen | 46 | 17 |
| Sertraline Hcl | Sertraline Hcl | 46 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 46 | suppressed |
| Temazepam | Temazepam | 45 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 17 |
| Glipizide Er | Glipizide | 43 | 18 |
| Mupirocin | Mupirocin | 43 | 30 |
| Ipratropium Bromide | Ipratropium Bromide | 42 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 34 |
| Allopurinol | Allopurinol | 39 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | 16 |
| Clonidine Hcl | Clonidine Hcl | 36 | 13 |
| Ibu | Ibuprofen | 36 | 18 |
| Linzess | Linaclotide | 36 | 13 |
| Spironolactone | Spironolactone | 36 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 13 |
| Carvedilol | Carvedilol | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 25 |
| Penicillin V Potassium | Penicillin V Potassium | 32 | 23 |
| Torsemide | Torsemide | 32 | 12 |
| Alendronate Sodium | Alendronate Sodium | 31 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Glimepiride | Glimepiride | 29 | 13 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | 12 |
| Glipizide | Glipizide | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 22 |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | 11 |
| Celecoxib | Celecoxib | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | 12 |
| Levofloxacin | Levofloxacin | 23 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | 12 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | 11 |
| Jardiance | Empagliflozin | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 16 | 12 |
| Lunesta | Eszopiclone | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 13 | 13 |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $442.70 · 26 records | Novo Nordisk Inc | AIRSUPRA, CAPLYTA, FARXIGA, Ohtuvayre, Ozempic, PROCLAIM, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error